1. Home
  2. CREG vs NXTC Comparison

CREG vs NXTC Comparison

Compare CREG & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CREG

Smart Powerr Corp.

HOLD

Current Price

$1.14

Market Cap

27.1M

Sector

Utilities

ML Signal

HOLD

Logo NextCure Inc.

NXTC

NextCure Inc.

HOLD

Current Price

$12.34

Market Cap

24.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CREG
NXTC
Founded
N/A
2015
Country
China
United States
Employees
N/A
N/A
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.1M
24.6M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
CREG
NXTC
Price
$1.14
$12.34
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$23.00
AVG Volume (30 Days)
62.6K
58.8K
Earning Date
11-13-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$173,659.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.02
$2.69
52 Week High
$14.70
$15.74

Technical Indicators

Market Signals
Indicator
CREG
NXTC
Relative Strength Index (RSI) 39.12 56.76
Support Level $1.20 $10.81
Resistance Level $1.27 $13.44
Average True Range (ATR) 0.11 1.32
MACD -0.02 0.01
Stochastic Oscillator 10.00 50.29

Price Performance

Historical Comparison
CREG
NXTC

About CREG Smart Powerr Corp.

Smart Powerr Corp is a pioneer in waste energy recycling and a developer of energy efficiency solutions for various energy-intensive industries in China. It uses the Build-Operate-Transfer (BOT) model to provide energy-saving and recovery facilities for multiple energy-intensive industries in China. Its waste energy recycling projects allow customers which use substantial amounts of electricity to recapture previously wasted pressure, heat, and gas from their manufacturing processes to generate electricity. The company offers waste energy recycling systems to companies for use in nonferrous metal plants. It constructs its projects at its customer's facility and the electricity produced is used on-site by the customer.

About NXTC NextCure Inc.

NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.

Share on Social Networks: